Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Lucia da Ros"'
Autor:
Gianmaria Miolo, Wally Marus, Angela Buonadonna, Lucia Da Ros, Lara Della Puppa, Giuseppe Corona
Publikováno v:
Diagnostics, Vol 14, Iss 9, p 888 (2024)
The immunohistochemical assessment of mismatch repair (MMR) proteins represents a pivotal screening tool for identifying Lynch syndrome (LS)-related cancers, as the loss of their expression often indicates MMR dysfunction associated with genetic or e
Externí odkaz:
https://doaj.org/article/1b3f1944a3d848f6a86b1e000093920d
Autor:
Francesco Di Pierro, Francesco Sinatra, Maddalena Cester, Lucia Da Ros, Mara Pistolato, Vania Da Parè, Laura Fabbro, Daniela Maccari, Silvia Dotto, Sara Sossai, Gemma Fabozzi, Alexander Bertuccioli, Massimiliano Cazzaniga, Martino Recchia, Nicola Zerbinati, Luigina Guasti, Andrea Baffoni
Publikováno v:
Microorganisms, Vol 11, Iss 11, p 2796 (2023)
The aim of our study was to retrospectively evaluate whether the oral administration of L. crispatus (M247) could increase pregnancy and live birth rates in women undergoing assisted reproductive technology procedures. Enrolled women (N = 160) were d
Externí odkaz:
https://doaj.org/article/49d9d8d6f4b84bcf86af94166fe8c9c4
Autor:
Debora Basile, Lorenzo Gerratana, Carla Corvaja, Giacomo Pelizzari, Giorgia Franceschin, Elisa Bertoli, Lorenza Palmero, Diego Zara, Martina Alberti, Silvia Buriolla, Lucia Da Ros, Marta Bonotto, Mauro Mansutti, Simon Spazzapan, Marika Cinausero, Alessandro Marco Minisini, Gianpiero Fasola, Fabio Puglisi
Publikováno v:
Breast, Vol 57, Iss , Pp 104-112 (2021)
Background: Endocrine therapy (ET) plus cyclin-dependent-kinases 4/6 inhibitors (CDK4/6i) represents the standard treatment for luminal-metastatic breast cancer (MBC). However, prospective head-to-head comparisons are still lacking for 1st line (L) o
Externí odkaz:
https://doaj.org/article/ffca05a7c1374d128a76cb6fc5f88ba4
Autor:
Lorenzo Gerratana, Debora Basile, Alessandra Franzoni, Lorenzo Allegri, Davide Viotto, Carla Corvaja, Lucia Bortot, Elisa Bertoli, Silvia Buriolla, Giada Targato, Lucia Da Ros, Stefania Russo, Marta Bonotto, Barbara Belletti, Gustavo Baldassarre, Giuseppe Damante, Fabio Puglisi
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
BackgroundEndocrine therapy (ET) is the mainstay of treatment for hormone receptor-positive human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer; however, adaptive mechanisms emerge in about 25–30% of cases through alte
Externí odkaz:
https://doaj.org/article/cc9ff308591747ecb18dbb45a2610636
Autor:
Mattia Garutti, Alessandro Marco Minisini, Lucia Da Ros, Giacomo Pelizzari, C. Lisanti, Marta Bonotto, Simon Spazzapan, Mauro Mansutti, Debora Avoledo, Lorenzo Gerratana, Silvia Bolzonello, M. Giavarra, Debora Basile, E. Bertoli, L. Bortot, Michele Bartoletti, Gianpiero Fasola, Fabio Puglisi, S. Buriolla, Paola Di Nardo, C. Corvaja
Publikováno v:
Cancer Research. 80:P5-14
Background: The combination of endocrine therapy with the cyclin-dependent kinases 4/6 inhibitor palbociclib was proven to be effective for the treatment of hormone receptor (HR)-positive/HER2-negative metastatic breast cancer (MBC). Although general
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0064547c9cb3b0b4cd889608f9e9da46
https://doi.org/10.1158/1538-7445.sabcs19-p5-14-08
https://doi.org/10.1158/1538-7445.sabcs19-p5-14-08
Autor:
Mattia Garutti, Lorenzo Foffano, Roberta Mazzeo, Anna Michelotti, Lucia Da Ros, Alessandra Viel, Gianmaria Miolo, Alberto Zambelli, Fabio Puglisi
Publikováno v:
Genes. 14:1025
Hereditary cancer syndromes account for nearly 10% of cancers even though they are often underdiagnosed. Finding a pathogenic gene variant could have dramatic implications in terms of pharmacologic treatments, tailored preventive programs, and famili
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4582e5cd6990a222e9b2c94f97ddbc2e
https://doi.org/10.3390/genes14051025
https://doi.org/10.3390/genes14051025
Autor:
Tania Pivetta, Brenno Pastò, Martina Urbani, Elisabetta Benozzi, Nicola De Pascalis, Tiziana Perin, Mario Mileto, Bruno Pasquotti, Erica Piccoli, Lorenzo Vinante, Chiara Bampo, Silvia Bolzonello, Mattia Garutti, Milena Nicoloso, Serena Corsetti, Simona Scalone, Lucia da Ros, Paola di Nardo, Camilla Lisanti, Simon Spazzapan, Barbara Belletti, Michele Bartoletti, Lorenzo Gerratana, Samuele Massarut, Fabio Puglisi
Publikováno v:
Cancer Research. 83:P4-02
Background: Over the last years, the management of patients with node positive early breast cancer has gone through important innovations. On the medical side, new targeted therapies such as olaparib and abemaciclib have been introduced, with promisi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::02cf7dcbe8e96aac1a95eee17cafd598
https://doi.org/10.1158/1538-7445.sabcs22-p4-02-06
https://doi.org/10.1158/1538-7445.sabcs22-p4-02-06
Autor:
Sandra Orrù, Rubina Manuela Trimboli, Fiorenza De Rose, Fabio Puglisi, Carlo Cabula, A. Ciabattoni, Lucia Da Ros, Massimo Maria Grassi, Isabella Castellano, Bruno Meduri
Publikováno v:
Medical Oncology. 38
The multidisciplinary management represents a crucial part of the care for cancer patients, resulting in better clinical and process outcomes, with evidence of improved survival among different cancer primary sites, including breast. According with i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31596dfe466111b1a07a6c06b143ea2b
https://doi.org/10.1007/s12032-021-01514-w
https://doi.org/10.1007/s12032-021-01514-w
Autor:
Michele Bartoletti, Marcella Montico, Roberta Mazzeo, Marco De Scordilli, Lucia Musacchio, Emilio Lucia, Giorgio Giorda, Samuele Massarut, Martina Urbani, Gianmaria Miolo, Alessandra Viel, Mattia Garutti, Lucia Da Ros, Simona Scalone, Milena Nicoloso, Serena Corsetti, Roberto Sorio, Domenica Lorusso, Sandro Pignata, Fabio Puglisi
Publikováno v:
Journal of Clinical Oncology. 40:5566-5566
5566 Background: As the prognosis of BRCA-related advanced ovarian cancer (AOC) continues to improve thanks to the introduction of targeted therapies like poly ADP-ribose polymerase inhibitors (PARPi) and bevacizumab, the occurrence of second primary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d3d97f9751b9c49c0807756dc3675945
https://doi.org/10.1200/jco.2022.40.16_suppl.5566
https://doi.org/10.1200/jco.2022.40.16_suppl.5566
Autor:
M. Alberti, Fabio Puglisi, Giorgia Franceschin, Marta Bonotto, D. Zara, Simon Spazzapan, L. Palmero, Debora Basile, E. Bertoli, C. Corvaja, Alessandro Marco Minisini, Marika Cinausero, Lorenzo Gerratana, S. Buriolla, Lucia Da Ros, Giacomo Pelizzari, Gianpiero Fasola, Mauro Mansutti
Publikováno v:
Breast, Vol 57, Iss, Pp 104-112 (2021)
The Breast : Official Journal of the European Society of Mastology
The Breast : Official Journal of the European Society of Mastology
Background Endocrine therapy (ET) plus cyclin-dependent-kinases 4/6 inhibitors (CDK4/6i) represents the standard treatment for luminal-metastatic breast cancer (MBC). However, prospective head-to-head comparisons are still lacking for 1st line (L) op
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69f4456b9e92ccd7eec542a8dbb1b44e
http://hdl.handle.net/11390/1207516
http://hdl.handle.net/11390/1207516
